The data giant that powers the global pharmaceutical pipeline
In short: How do new medicines reach the market? They rely on a massive infrastructure of clinical trials and patient data. IQVIA sits at the center of this ecosystem, managing the transition from laboratory research to global commercialization by processing billions of records and coordinating the world's largest clinical studies.
Formed in 2016 through the merger of Quintiles and IMS Health, IQVIA has become a dominant force in health information technology and clinical research. By joining forces, Quintiles—a global leader in commercial outsourcing and biopharmaceutical development—united with IMS Health, a major entity for analytics and healthcare data. This union created a $17.6 billion entity capable of handling every stage of a drug's lifecycle, from initial protocol design and patient recruitment to post-approval regulatory affairs.
The company's scale is defined by its massive data footprint. Over one billion patient records, which are presumed to be anonymous, are held by the Technology & Analytics branch on a global scale. This data serves as the backbone for healthcare analytics, cloud-based customer relationship management software, and consulting services for hospitals, pharmacists, and life science organizations. By leveraging these assets, IQVIA helps companies navigate the complexities of global health markets, including specialized coverage for regions like China.
IQVIA's operations are divided into three primary segments: Research & Development Solutions, which accounts for 55% of 2024 revenues; Technology & Analytics Solutions, making up 40%; and Contract Sales & Medical Solutions, contributing 5%. This structure allows them to act as a comprehensive contract research organization (CRO), managing clinical trials from Phase I through IV. Their influence is cemented by a history of strategic acquisitions, including firms specializing in market intelligence, software development, and patient-centric claims data, ensuring they remain the primary intermediary between scientific innovation and commercial availability.
The firm's origins date to 1974, the year Dennis Gillings secured an initial agreement to offer pharmaceutical firms consulting on data management and statistics. Since then, the organization has expanded through a series of high-profile acquisitions and corporate restructurings, including a 1998 split from Cognizant Corporation. Today, it operates as a global leader, providing the essential infrastructure that allows the pharmaceutical and biotechnology industries to function at scale.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: IQVIA
To cite this card, link to https://intellectplus.co.uk/app/wealth-iqvia.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Companies · More in Wealth & Business · Latest · A–Z · All topics
